ANXA1 and glioma: As we know, the MGMT promoter methylated status has a confirmed association with TMZ therapy in GBMs; thus, we imply that ANXA1 not only functions as an important factor of the post-surgery recurrence of glioma but also results in the resistance of TMZ chemotherapy.